SCHEMBL1649941

SCHEMBL1649941

COc1c(-c2cocn2)ccc(CS(=O)(=O)c2ccccc2)c1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.36
ALOX5AP P20292 1/20 0.36
NPC1 O15118 3/20 0.35
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KMT2A Q03164 2/20 0.35
IMPDH2 P12268 4/20 0.35
IMPDH1 P20839 1/20 0.35
KEAP1 Q14145 5/20 0.35
NFE2L2 Q16236 2/20 0.35
METAP2 P50579 1/20 0.35
PTGDR Q13258 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
HSD11B1 P28845 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648097 0.92 KMT2A (0.36) LTB4RLTB4R2ALOX5APNPC1ALDH1A1
SCHEMBL1649154 0.82 NPC1 (0.38) ALOX5APNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL1647754 0.81 KMT2A (0.43) ALOX5APNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL1647925 0.81 KMT2A (0.36) ALOX5APNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL1647756 0.81 METAP2 (0.53) NPC1ALDH1A1RAB9ASMN1; SMN2KMT2A
SCHEMBL18801404 0.80 KMT2A (0.38) LTB4RLTB4R2NPC1ALDH1A1RAB9A
SCHEMBL1648368 0.79 IMPDH2 (0.43) IMPDH2IMPDH1
SCHEMBL1648553 0.78 CSNK1A1 (0.38) ALOX5APALDH1A1KMT2AKEAP1NFE2L2
SCHEMBL1649016 0.78 METAP2 (0.47) ALDH1A1KMT2AKEAP1NFE2L2METAP2
SCHEMBL1646328 0.77 ALDH1A1 (0.39) ALOX5APALDH1A1SMN1; SMN2KMT2AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP claimed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US claimed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US claimed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP claimed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO claimed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS LTB4R 2943/4885LTB4R2 2096/4885ALOX5AP 1081/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS LTB4R 2943/4885LTB4R2 2096/4885ALOX5AP 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.